FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.

Nathan Fowler,Joseph Pearlberg,Les H. Brail,Weiliang Shi,Liewen Jiang,Carrie Condon,Mathias Rummel

FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.

2016

Nathan Fowler
Joseph Pearlberg
Les H. Brail
Weiliang Shi
Liewen Jiang
Carrie Condon
Mathias Rummel

TPS7578Background: Most patients with follicular lymphoma (FL) experience a durable response after initial chemotherapy, however approximately 20% relapse within 24 months of initial treatment. The...

Keywords:

Randomized controlled trial
Oncology
Rituximab
Duvelisib
Refractory Follicular Lymphoma
Chemotherapy regimen
Internal medicine
Medicine
CHOP
Pathology
Surgery
in patient
Chemotherapy
relapsed refractory
Follicular lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations